Bayesian Capital Management’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.07M | Buy |
48,500
+24,900
| +106% | +$1.35M | 1.32% | 10 |
|
|
2026
Q1 | $1.48M | Buy |
+23,600
| New | +$1.89M | 1.81% | 11 |
|
|
2025
Q4 | – | Sell |
-55,200
| Closed | -$5.39M | – | 177 |
|
|
2025
Q3 | $5.39M | Buy |
+55,200
| New | +$5.72M | 1.1% | 3 |
|
|
2025
Q2 | – | Sell |
-4,900
| Closed | -$494K | – | 566 |
|
|
2025
Q1 | $494K | Sell |
4,900
-8,200
| -63% | -$826K | 0.08% | 296 |
|
|
2024
Q4 | $1.17M | Sell |
13,100
-23,700
| -64% | -$2.09M | 0.14% | 209 |
|
|
2024
Q3 | $3.08M | Sell |
36,800
-6,500
| -15% | -$512K | 0.36% | 68 |
|
|
2024
Q2 | $3.33M | Sell |
43,300
-900
| -2% | -$65.9K | 0.38% | 55 |
|
|
2024
Q1 | $3.03M | Sell |
44,200
-1,200
| -3% | -$77.2K | 0.29% | 91 |
|
|
2023
Q4 | $2.62M | Buy |
45,400
+22,000
| +94% | +$1.17M | 0.28% | 92 |
|
|
2023
Q3 | $1.24M | Buy |
23,400
+12,800
| +121% | +$671K | 0.14% | 181 |
|
|
2023
Q2 | $573K | Sell |
10,600
-75,200
| -88% | -$3.93M | 0.06% | 377 |
|
|
2023
Q1 | $4.29M | Buy |
85,800
+60,712
| +242% | +$2.86M | 0.53% | 32 |
|
|
2022
Q4 | $1.16M | Buy |
+25,088
| New | +$1.09M | 0.17% | 151 |
|
|
2022
Q3 | – | Sell |
-53,788
| Closed | -$2M | – | 719 |
|
|
2022
Q2 | $2M | Buy |
53,788
+3,100
| +6% | +$126K | 0.37% | 48 |
|
|
2022
Q1 | $2.25M | Sell |
50,688
-46,901
| -48% | -$2.03M | 0.34% | 54 |
|
|
2021
Q4 | $4.15M | Buy |
97,589
+56,200
| +136% | +$2.36M | 1.31% | 11 |
|
|
2021
Q3 | $1.8M | Buy |
41,389
+27,600
| +200% | +$1.22M | 0.52% | 43 |
|
|
2021
Q2 | $590K | Sell |
13,789
-24,611
| -64% | -$1.04M | 0.15% | 169 |
|
|
2021
Q1 | $1.48M | Sell |
38,400
-93,900
| -71% | -$3.55M | 0.34% | 72 |
|
|
2020
Q4 | $4.76M | Buy |
132,300
+80,700
| +156% | +$2.91M | 1.24% | 10 |
|
|
2020
Q3 | $1.97M | Buy |
51,600
+9,700
| +23% | +$374K | 0.48% | 45 |
|
|
2020
Q2 | $1.47M | Buy |
41,900
+7,300
| +21% | +$263K | 0.32% | 74 |
|
|
2020
Q1 | $1.13M | Buy |
34,600
+20,700
| +149% | +$809K | 0.24% | 101 |
|
|
2019
Q4 | $629K | Buy |
+13,900
| New | +$582K | 0.11% | 258 |
|
|
2017
Q2 | – | Sell |
-39,600
| Closed | -$985K | – | 440 |
|
|
2017
Q1 | $985K | Buy |
+39,600
| New | +$963K | 0.47% | 41 |
|
|
2016
Q4 | – | Sell |
-33,900
| Closed | -$807K | – | 605 |
|
|
2016
Q3 | $807K | Sell |
33,900
-8,400
| -20% | -$200K | 0.53% | 46 |
|
|
2016
Q2 | $989K | Buy |
+42,300
| New | +$915K | 0.59% | 22 |
|
Other funds holding BSX
Bayesian Capital Management's BSX Position: Q2 2026 in Review
Bayesian Capital Management increased its Boston Scientific (BSX) stake by 106% in Q2 2026, buying an estimated $1.35M and bringing the position to 48,500 shares worth $2.07M. The position accounts for 1.32% of the portfolio, ranked #10.
Bayesian Capital Management first reported a position in BSX in Q2 2016 and has held it in 27 quarters since. The position peaked at $5.39M in Q3 2025. 1,470 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Bayesian Capital Management held 48,500 shares of Boston Scientific worth $2.07M as of Q2 2026.
- Bayesian Capital Management bought 24,900 Boston Scientific shares in Q2 2026, an estimated $1.35M.
- Boston Scientific made up 1.32% of Bayesian Capital Management's portfolio in Q2 2026, its #10 holding.
- Bayesian Capital Management first reported a position in Boston Scientific in Q2 2016 and has held it in 27 quarters since.
- Bayesian Capital Management's Boston Scientific position peaked at $5.39M in Q3 2025.
- 1,470 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.